Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have received a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $66.1250.

VOR has been the subject of a number of analyst reports. TD Cowen initiated coverage on Vor Biopharma in a research report on Wednesday, December 17th. They issued a “buy” rating for the company. JPMorgan Chase & Co. lowered their price objective on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Citigroup started coverage on Vor Biopharma in a research note on Friday, January 9th. They set a “buy” rating and a $50.00 price objective for the company. Wedbush initiated coverage on shares of Vor Biopharma in a report on Tuesday, November 25th. They issued a “neutral” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, January 21st.

Vor Biopharma Stock Performance

Shares of Vor Biopharma stock opened at $13.76 on Thursday. The stock has a market cap of $143.24 million, a P/E ratio of -0.04 and a beta of 1.99. The stock’s fifty day moving average is $14.33 and its 200 day moving average is $19.66. Vor Biopharma has a one year low of $2.62 and a one year high of $65.80.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new position in Vor Biopharma in the 4th quarter worth $36,000. Goldman Sachs Group Inc. lifted its position in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Vor Biopharma in the second quarter worth about $66,000. Chung Wu Investment Group LLC bought a new position in shares of Vor Biopharma in the fourth quarter worth about $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new stake in shares of Vor Biopharma during the fourth quarter worth about $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).